MTR Combo
MTR Combo is an investigational minimally invasive therapy designed for mitral and tricuspid biventricular patient population. The system combines left-ventricular remodeling for proportionate functional mitral regurgitation with coaptation support for tricuspid regurgitation through a novel spacer system, bringing both approaches together in a single procedure. By addressing both conditions within one intervention, MTR Combo is intended to reduce procedural burden and support a more unified treatment strategy for patients with advanced heart failure associated with dual-valve dysfunction.Developed from NIH research with 19 human cases, the approach has since been applied in 5 additional cases by Tau Medical.
Pre-Implantation
Post-Implantation
Unmet Need
Patients with coexisting functional mitral regurgitation and tricuspid regurgitation represent a high-need population with limited transcatheter treatment options. In the United States, functional mitral regurgitation affects an estimated 2 million patients, and approximately one-third of these patients also have significant tricuspid regurgitation. This creates a large population of patients with dual-valve disease, many of whom may be suitable candidates for transcatheter intervention.
Mayo Clinic Collaboration
Tau Medical is working with Mayo Clinic* to advance development of MTR Combo. The program is focused on further development of a transfemoral delivery system, expansion of intellectual property, and validation through a First-in-Human / Early Feasibility Study. Clinical leadership associated with the program includes Dr. Mayra Guerrero and Dr. Mohamad Alkhouli.
*Mayo Clinic has a financial interest in the technology here referenced. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Clinical Development Team
MTR Combo is supported by a clinical team with deep expertise in structural heart intervention, transcatheter valve therapies, and translational device development. The group provides guidance across procedural design, clinical strategy, and future feasibility evaluation. Clinical leadership in Korea is led by Dr. Minku Chon of Pusan National University Hospital, with additional leadership from Dr. Lee Chul Hyun of Keimyung University Dongsan Hospital. Mayo Clinic clinical leadership is led by Dr. Mayra Guerrero and Dr. Mohamad Alkhouli. Together, the team provides guidance across procedural design, clinical strategy, and future feasibility evaluation.
PNU - KMU, South Korea
Dr. Minku Chon
M.D., Ph.D.
Interventional Cardiologist
Pusan National Univ. Hospital
Dr. Lee Chul Hyun
M.D.
Interventional Cardiologist
Keimyung Univ. Hospital
Mayo Clinic, USA
M.D.
Interventional Cardiologist
Mayo Clinic
M.D., M.B.A.
Interventional Cardiologist
Mayo Clinic
